Wedbush Reiterates Outperform on Vor Biopharma, Maintains $11 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten reiterates an Outperform rating on Vor Biopharma (NASDAQ:VOR) and maintains an $11 price target.
May 10, 2024 | 1:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst David Nierengarten reaffirmed an Outperform rating on Vor Biopharma, with a price target of $11, indicating a positive outlook on the company's stock.
Analyst ratings, especially those with a positive outlook such as an Outperform rating, can influence investor sentiment and potentially lead to an increase in stock price. Maintaining a price target significantly above the current trading price suggests confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100